Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 140

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 140
---
   |     |   |       |
| Increase (decrease) in historical net tangible book value per share attributable to pro forma    
 adjustments described above                                                                      |     |   | (38.24 | ) |     |   |       |
| Pro forma net tangible book value per share as of June 30, 2025                                  |     |   |   3.03 |   |     |   |       |
| Increase in pro forma net tangible book value per share attributable to new investors purchasing 
 shares from us in this offering                                                                  |     |   |   8.85 |   |     |   |       |
| Pro forma as adjusted net tangible book value per share after this offering                      |     |   |        |   |     |   | 11.88 |
| Dilution per share to new investors participating in this offering                               |     |   |        |   |     | $ |  3.12 |

The dilution information discussed above is illustrative only and will change based on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase (decrease) in the assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted net tangible book value per share after this offering by approximately $(0.77), and dilution in pro forma net tangible book value per share to new investors by approximately $0.22, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the underwriting discounts and commissions payable by us. Each increase of 1.0 million shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase our pro forma as adjusted net tangible book value per share after this offering by approximately $0.10 and decrease the dilution to investors participating in this offering by approximately $(0.10) per share, assuming that the assumed initial public offering price remains the same, and 93

after deducting the estimated underwriting discounts and commissions. Similarly, each decrease of 1.0 million shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would decrease the pro forma as adjusted net tangible book value per share after this offering by approximately $(0.11